Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America

Patients with primary immunodeficiency disease (PIDD) typically require life-long intravenous (IV) or subcutaneous (SC) immunoglobulin (Ig) replacement therapy to prevent recurrent infections. The efficacy, safety, and pharmacokinetics of a highly concentrated (20 %) Ig preparation for SC administra...

Descripción completa

Detalles Bibliográficos
Autores principales: Suez, Daniel, Stein, Mark, Gupta, Sudhir, Hussain, Iftikhar, Melamed, Isaac, Paris, Kenneth, Darter, Amy, Bourgeois, Christelle, Fritsch, Sandor, Leibl, Heinz, McCoy, Barbara, Gelmont, David, Yel, Leman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018260/
https://www.ncbi.nlm.nih.gov/pubmed/27582171
http://dx.doi.org/10.1007/s10875-016-0327-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5018260/
https://www.ncbi.nlm.nih.gov/pubmed/27582171
http://dx.doi.org/10.1007/s10875-016-0327-9

Ejemplares similares